Molecular Partners AG – SIX:MOLN.SW
Molecular Partners AG stock price today
Molecular Partners AG stock price monthly change
Molecular Partners AG stock price quarterly change
Molecular Partners AG stock price yearly change
Molecular Partners AG key metrics
Market Cap | 167.91M |
Enterprise value | 93.67M |
P/E | 1.52 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 0.91 |
Price/Book | 0.73 |
PEG ratio | N/A |
EPS | -1.78 |
Revenue | 6.72M |
EBITDA | -57.19M |
Income | -58.53M |
Revenue Q/Q | -10.22% |
Revenue Y/Y | -66.07% |
Profit margin | 62.17% |
Oper. margin | 61.52% |
Gross margin | 0% |
EBIT margin | 61.52% |
EBITDA margin | -850.34% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMolecular Partners AG stock price history
Molecular Partners AG stock forecast
Molecular Partners AG financial statements
| Jun 2023 | 415K | -15.98M | -3852.29% |
|---|---|---|---|
| Sep 2023 | 2.54M | -11.43M | -450.18% |
| Dec 2023 | 1.03M | -19.78M | -1916.67% |
| Mar 2024 | 2.73M | -11.32M | -413.62% |
| 2025 | 18.66M | -61.78M | -331.1% |
|---|---|---|---|
| 2026 | 17.79M | -81.00M | -455.34% |
| 2027 | 75M | -67.17M | -89.57% |
| 2028 | 120M | -47.51M | -39.6% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 230493000 | 24.51M | 10.64% |
|---|---|---|---|
| Sep 2023 | 218118000 | 21.90M | 10.04% |
| Dec 2023 | 198352000 | 21.92M | 11.05% |
| Mar 2024 | 185605000 | 17.06M | 9.19% |
| Jun 2023 | -13.28M | 4.03M | -274K |
|---|---|---|---|
| Sep 2023 | -13.19M | 17.77M | -298K |
| Dec 2023 | -14.86M | 18.33M | -298K |
| Mar 2024 | -15.78M | 16.34M | -300K |
Molecular Partners AG alternative data
| Aug 2023 | 175 |
|---|---|
| Sep 2023 | 168 |
| Oct 2023 | 168 |
| Nov 2023 | 175 |
| Dec 2023 | 175 |
| Jan 2024 | 175 |
| Feb 2024 | 175 |
| Mar 2024 | 167 |
| Apr 2024 | 167 |
| May 2024 | 167 |
| Jun 2024 | 167 |
| Jul 2024 | 167 |
Molecular Partners AG other data
| Patent |
|---|
Application Filling date: 3 Jun 2020 Issue date: 4 Aug 2022 |
Application Filling date: 11 Feb 2022 Issue date: 28 Jul 2022 |
Application Filling date: 2 Aug 2021 Issue date: 7 Apr 2022 |
Application Filling date: 12 Aug 2021 Issue date: 3 Mar 2022 |
Application Filling date: 14 May 2021 Issue date: 23 Dec 2021 |
Application Filling date: 6 May 2021 Issue date: 11 Nov 2021 |
Application Filling date: 22 Jun 2020 Issue date: 6 May 2021 |
Application Filling date: 9 Apr 2020 Issue date: 11 Mar 2021 |
Application Filling date: 3 Jun 2020 Issue date: 10 Dec 2020 |
Grant Filling date: 20 Sep 2017 Issue date: 21 Jul 2020 |
| Insider | Compensation |
|---|---|
Dr. Patrick Amstutz (1975) Co-Founder, Chief Executive Officer, Member of Management Board & Director | $657,000 |
-
What's the price of Molecular Partners AG stock today?
One share of Molecular Partners AG stock can currently be purchased for approximately $18.
-
When is Molecular Partners AG's next earnings date?
Unfortunately, Molecular Partners AG's (MOLN.SW) next earnings date is currently unknown.
-
Does Molecular Partners AG pay dividends?
No, Molecular Partners AG does not pay dividends.
-
How much money does Molecular Partners AG make?
Molecular Partners AG has a market capitalization of 167.91M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 96.29% to 7.04M US dollars.
-
What is Molecular Partners AG's stock symbol?
Molecular Partners AG is traded on the SIX under the ticker symbol "MOLN.SW".
-
What is Molecular Partners AG's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Molecular Partners AG?
Shares of Molecular Partners AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Molecular Partners AG's key executives?
Molecular Partners AG's management team includes the following people:
- Dr. Patrick Amstutz Co-Founder, Chief Executive Officer, Member of Management Board & Director(age: 50, pay: $657,000)
-
Is Molecular Partners AG founder-led company?
Yes, Molecular Partners AG is a company led by its founder Dr. Patrick Amstutz.
-
How many employees does Molecular Partners AG have?
As Jul 2024, Molecular Partners AG employs 167 workers.
-
When Molecular Partners AG went public?
Molecular Partners AG is publicly traded company for more then 10 years since IPO on 3 Mar 2015.
-
What is Molecular Partners AG's official website?
The official website for Molecular Partners AG is molecularpartners.com.
-
How can i contact Molecular Partners AG?
Molecular Partners AG can be reached via phone at +41 44 755 77 00.
Molecular Partners AG company profile:
Molecular Partners AG
molecularpartners.comSIX
167
Biotechnology
Healthcare
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Schlieren, 8952
:
ISIN: CH0256379097
:
